Skip to main content

Table 2 Hazard ratios for psoriasis in the nationwide breast cancer cohort

From: Risk and predictors of psoriasis in patients with breast cancer: a Swedish population-based cohort study

 

No. of PYs

Any psoriasis

Psoriasis vulgaris

Palmoplantar pustulosis

Arthropathic psoriasis

Total/case no.

HR (95% CI)

Case no.

HR (95% CI)

Case no.

HR (95% CI)

Case no.

HR (95% CI)

Overall

 Matched reference cohort

1,666,038

280,854/2795

1.00 (Ref.)

1234

1.00 (Ref.)

488

1.00 (Ref.)

433

1.00 (Ref.)

 Breast cancer cohort

307,684.8

56,235/599

1.17 (1.07–1.28)

298

1.33 (1.17–1.52)

95

1.04 (0.84–1.30)

75

0.94 (0.73–1.20)

Time since diagnosis

0 to < 0.5 year

  Matched reference cohort

139,886.5

280,854/238

1.00 (Ref.)

86

1.00 (Ref.)

48

1.00 (Ref.)

51

1.00 (Ref.)

  Breast cancer cohort

27,780.35

56,235/50

1.08 (0.80–1.47)

23

1.35 (0.85–2.14)

13

1.40 (0.76–2.59)

4

0.41 (0.15–1.13)

0.5 to < 1 year

  Matched reference cohort

138,587.1

278,473/228

1.00 (Ref.)

113

1.00 (Ref.)

27

1.00 (Ref.)

32

1.00 (Ref.)

  Breast cancer cohort

27,301.1

55,033/75

1.68 (1.30–2.19)

37

1.66 (1.15–2.41)

15

2.88 (1.52–5.43)

5

0.80 (0.31–2.07)

1–5 years

  Matched reference cohort

861,202.7

275,870/1451

1.00 (Ref.)

629

1.00 (Ref.)

281

1.00 (Ref.)

219

1.00 (Ref.)

  Breast cancer cohort

162,011.6

54,156/296

1.09 (0.96–1.24)

146

1.27 (1.06–1.52)

43

0.81 (0.58–1.12)

44

1.07 (0.77–1.48)

   > 5 years

  Matched reference cohort

526,362

159,147/878

1.00 (Ref.)

406

1.00 (Ref.)

132

1.00 (Ref.)

131

1.00 (Ref.)

  Breast cancer cohort

90,591.81

28,430/178

1.17 (0.99–1.38)

92

1.33 (1.06–1.68)

24

1.02 (0.66–1.60)

22

0.98 (0.62–1.56)

Age at breast cancer diagnosis

20–44 years

  Matched reference cohort

158,527.2

25,361/185

1.00 (Ref.)

75

1.00 (Ref.)

30

1.00 (Ref.)

46

1.00 (Ref.)

  Breast cancer cohort

28,908.36

5099/43

1.35 (0.97–1.90)

24

1.88 (1.17–3.00)

6

1.08 (0.45–2.62)

6

0.82 (0.35–1.94)

45–54 years

  Matched reference cohort

389,187.5

61,404/707

1.00 (Ref.)

285

1.00 (Ref.)

155

1.00 (Ref.)

122

1.00 (Ref.)

  Breast cancer cohort

72,753.48

12,289/151

1.16 (0.97–1.38)

72

1.39 (1.07–1.81)

28

0.95 (0.63–1.43)

22

0.97 (0.61–1.53)

55–64 years

  Matched reference cohort

549,425.4

89,347/1067

1.00 (Ref.)

447

1.00 (Ref.)

213

1.00 (Ref.)

172

1.00 (Ref.)

  Breast cancer cohort

102,753.2

17,850/229

1.14 (0.99–1.32)

109

1.27 (1.03–1.58)

42

1.04 (0.74–1.45)

23

0.74 (0.47–1.15)

65–80 years

  Matched reference cohort

568,898.3

104,742/836

1.00 (Ref.)

427

1.00 (Ref.)

90

1.00 (Ref.)

93

1.00 (Ref.)

  Breast cancer cohort

103,269.8

20,997/176

1.16 (0.99–1.38)

93

1.27 (1.01–1.59)

19

1.21 (0.73–2.01)

24

1.30 (0.82–2.07)

  1. CI confidence interval, no. number, PYs person-years, HR hazard ratio
  2. Hazard ratio of psoriasis in the nationwide breast cancer cohort compared to age, residence place, and social economic status matched Swedish female population (age 20–80). Significant associations are denoted in boldface. P values for the test of interaction term of breast cancer diagnosis and age groups are 0.84, 0.49, 0.91, and 0.37, respectively, for psoriasis overall, psoriasis vulgaris, palmoplantar pustulosis, and arthropathic psoriasis